Search

Displaying results 2511 - 2520 of 4600 in total
  1. Drug

    Dithiazanine

    go.drugbank.com/drugs/DB11516
    ApprovedVet approvedWithdrawn

    Dithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032]

  2. Drug

    Fludiazepam

    go.drugbank.com/drugs/DB01567
    IllicitInvestigational

    It is a scheduled drug in the U.S., but is approved for use in Japan.

  3. Drug

    Tiopronin

    go.drugbank.com/drugs/DB06823
    Approved

    It is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects.

  4. Drug

    Cilnidipine

    go.drugbank.com/drugs/DB09232
    Investigational

    It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995.

  5. Drug

    Dimercaprol

    go.drugbank.com/drugs/DB06782
    Approved

    Dimercaprol has toxic potential, and its use may be followed by a variety of adverse effects. … Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II.

  6. Drug

    Ulevostinag

    go.drugbank.com/drugs/DB14721
    Investigational

    Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T lymphocytes (CTLs). … Upon intratumoral (IT) administration, STING agonist MK-1454 binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear

  7. Drug

    Teprotumumab

    go.drugbank.com/drugs/DB06343
    ApprovedInvestigational

    Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was approved by

  8. Drug

    Rurioctocog alfa pegol

    go.drugbank.com/drugs/DB16007
    ApprovedInvestigational

    It was first approved by the European Commission in January 2018. … [A245149] Hemophilia A is the most common inherited bleeding disorder leading to deficiency of factor VIII, which is caused by defects in the F8C gene that encodes coagulation factor VIII.

  9. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    [A263461] Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation.[L50336] … On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD

  10. Drug

    Fulvestrant

    go.drugbank.com/drugs/DB00947
    ApprovedInvestigational

    It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.